Result for
Tag: vaccine
May 10, 2021
Meta-Analysis of Risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia Following ChAdOx1-S Recombinant Vaccine
[Pre-print, not peer-reviewed] Pooled estimates of vaccine-induced immune thrombotic thrombocytopenia (VITT) cumulative incidence among individuals who received Oxford-AstraZeneca/Covishield vaccine in 10 countries found an overall risk of 1 in 139,000. For those aged 65 and over, the risk was about 1 in 1,000,000, while for those under 55, the risk was between 1 in 20,000…
May 7, 2021
Antibody Response to MRNA SARS-CoV-2 Vaccine among Kidney Transplant Recipients – Prospective Cohort Study
A study of kidney transplant recipients who received the Pfizer-BioNTech vaccine (N=308) found that only 36% tested positive for anti-SARS-CoV-2 antibodies 2-4 weeks after receiving the second dose. Factors associated with antibody detection included younger age, higher renal function, and reduced immunosuppression. The authors note that although correlation between antibody levels and protection has not…
May 6, 2021
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
The Pfizer-BioNTech vaccine was 90% effective against PCR-confirmed infection with the SARS-CoV-2 variant B.1.1.7 and 75% effective against the B.1351 variant 14 days after the second dose, according to a nationwide case-control analysis in Qatar through March 2021. Individuals with positive and negative PCR tests were matched on demographics and reason for PCR testing to…
May 4, 2021
Varicella-Zoster Virus Reactivation after SARS-Cov2 BNT162b2 MRNA Vaccination: Report of Five Cases
A series of 5 cases of herpes zoster reactivation were observed among a healthcare worker cohort in Spain that received at least the first dose of the Pfizer-BioNTech vaccine (n=3,707) over a period of four weeks. Three patients presented with herpes zoster after the first dose, while two presented after the second dose. All patients…
May 3, 2021
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021
A case series of 12 patients in the US who experienced cerebral venous sinus thrombosis (CVST) with thrombocytopenia following the Johnson & Johnson/Janssen vaccine found that all patients were women under the age of 60 who began experiencing symptoms that required hospitalization between 6 and 15 days after vaccination. Seven patients had at least 1…
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021
A case series of 12 patients in the US who experienced cerebral venous sinus thrombosis (CVST) with thrombocytopenia following the Johnson & Johnson/Janssen vaccine found that all patients were women under the age of 60 who began experiencing symptoms that required hospitalization between 6 and 15 days after vaccination. Seven patients had at least 1…
Prior SARS-CoV-2 Infection Rescues B and T Cell Responses to Variants after First Vaccine Dose
An analysis of B and T cell responses in healthcare workers who received one dose of the Pfizer-BioNTech vaccine showed that individuals with prior infection had enhanced T cell immunity and neutralizing antibodies effective against the B.1.1.7 and B.1.351 variants, while those without prior infection showed reduced immunity against variants. B.1.1.7 and B.1.351 spike mutations…
Weak Immunogenicity after a Single Dose of SARS-CoV-2 MRNA Vaccine in Treated Cancer Patients
Nearly half of patients with cancer (CP) at a hospital in France showed no anti-spike antibody response four weeks after one dose of the Pfizer-BioNTech vaccine, while 100% of healthcare workers (HCW) vaccinated at the same time (between February 17 and March 18, 2021) had developed anti-spike antibodies (seroconversion). Anti-S IgG titers were also significantly…
Real-World Effectiveness of Ad26.COV2.S Adenoviral Vector Vaccine for COVID-19
[Pre-print, not peer-reviewed] The Johnson & Johnson/Janssen vaccine showed a real-world effectiveness of 76.7% in preventing SARS-CoV-2 infection at least two weeks after vaccination among patients in the Mayo Clinic Health system, according to an analysis comparing the infection rate among 2,195 individuals who received the vaccine to that among 21,950 unvaccinated, propensity-matched individuals between…
April 28, 2021
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged =65 Years — United States, January–March 2021
Among adults age 65 and older (n = 417), mRNA vaccines were 94% effective against hospitalization for COVID-19 among fully vaccinated individuals, and 64% effective among partially-vaccinated individuals, according to data from US hospitals during January-March 2021. In the study, Pfizer and Moderna vaccines were equally represented, and approximately half of participants were over the…
Previous page Next page